---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-093346"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2026-08-10T20:04:20+00:00"
generated_at: "2026-08-10T20:05:12.799795+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q2 revenue up 9% to $85.7M, EPS $0.34, FY26 guidance narrowed

## Summary
- Q2 2026 revenue $85.7M, +9% YoY; net income $7.8M vs $3.2M; diluted EPS $0.34 vs $0.14
- Adjusted EBITDA $11.4M vs $7.7M; gross margin 76% vs 75%; lymphedema +12%, airway clearance -7%
- Six-month revenue $161.0M +15% YoY; net income $6.0M vs $0.2M; adjusted EBITDA $15.1M vs $7.4M
- FY2026 revenue guidance narrowed to $360-366M (from $360-368M); adjusted EBITDA maintained at $49-51M
- Exclusive U.S. VA/DoD distribution deal for ElastiMed's MyoSleeve; launched next-gen AffloVest; $5.3M share repurchase

## SEC filing metadata
- accession: 0001104659-26-093346
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2026-08-10T20:04:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000110465926093346/0001104659-26-093346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000110465926093346/tcmd-20260810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-093346
- JSON: https://secwatch.observer/filing/0001104659-26-093346.json
- Plain text: https://secwatch.observer/filing/0001104659-26-093346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.